Drawing for SEE.D

USPTO serial 79332683

SEE.D

Reviewed by CopyMark Law Group

Reg. 7292227Status 700Registered
Filing date
Status date
Registration date
Jan 30, 2024
Examiner
BELL, MARLENE D
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SEE.D?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Courtney Thompson

Courtney Thompson Fredrikson & Byron, P.A.60 South Sixth StreetSuite 1500Minneapolis, MN 55402

Goods and services

ClassDescriptionStatusFirst use
009Scientific, measuring apparatus and instruments namely system for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets; laboratory testing equipment, namely, glass slides, laboratory vials, test tubes, flasks for laboratory use, pipettor tips for laboratory use, racks, namely, vial racks, tip racks, slide racks, and reagent racks for laboratory use; diagnostic apparatus for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets for laboratory or research use; instruments for processing blood samples, namely, system for body fluids processing, glass slides, laboratory vials, test tubes, flasks for laboratory use, pipettor tips for laboratory use, racks, namely, vial racks, tip racks, slide racks, and reagent racks; laboratory automatic robotic systems for processing biological samples and managing reagents on carrier; instruments for managing biological samples in relation to diagnostics and oncology fields, namely laboratory instruments for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets for research or laboratory use in diagnostic and oncology fields; parts and fittings for all the aforesaid goods and the aforesaid goods in particular for laboratory diagnostic and research useACTIVE—
010Surgical and medical apparatus and instruments, namely, apparatus and instruments for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets; testing equipment, namely, blood testing apparatus; diagnostic apparatus, namely, diagnostic apparatus for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets for diagnostic and medical purposes; instruments for processing blood samples, namely, apparatus for blood analysis; automatic robot systems, namely, medical robots for processing biological samples and managing reagents on carrier, namely, medical robots for blood lysis protocols, medical robots for plasma extraction, medical robots for preparation of samples for cytological analysis, for nucleic acid extraction, for extracellular component analysis; instruments for managing biological samples, in particular for diagnosis including in oncology field, namely, medical instruments for body fluids processing for application in preparation for examination of liquid and corpuscular part, namely, cells, exosomes, nucleic acids, proteins, vesicles, metabolites, platelets for diagnostic and medical purposes in the oncology fields; parts and fittings for all the aforesaid goodsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 27, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 2, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 2, 2024FIMPFINAL DISPOSITION PROCESSED—
Apr 30, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 30, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 30, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 14, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 14, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 12, 2023GPNXNOTIFICATION PROCESSED BY IB—
Oct 25, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 25, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 25, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 7, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 6, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 6, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 6, 2023ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 25, 2023OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 8, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 8, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 8, 2023CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 5, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 5, 2023OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jun 7, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 6, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 6, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 4, 2023RFNTREFUSAL PROCESSED BY IB—
Dec 13, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 13, 2022RFRRREFUSAL PROCESSED BY MPU—
Sep 30, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 29, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2022DOCKASSIGNED TO EXAMINER—
Feb 11, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 7, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 3, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance